Andrea Anderson
Andrea Anderson covers genomics research studies and translational research for GenomeWeb. Find her on Twitter at @andyandy_tk.
Articles Authored by Andrea Anderson
Colorectal Cancer Studies Show Promise of Blood-, Stool-Based Screening
Research teams explored the performance of circulating cell-free DNA and stool DNA testing to find colorectal cancer in average-risk individuals.
Ovarian Cancer Detected Early With DNA From Pap Smear in Proof-of-Principle Study
Researchers developed an early ovarian cancer test based on DNA from Pap smears from women who went on to develop high-grade serous ovarian cancer.
Genomic Answers for Kids Team Releases Thousands of Genomes to Gain Insights Into Rare Diseases
Premium
The Children's Mercy Research Institute is using exome sequencing, genome sequencing, and other methods to diagnose and study rare pediatric conditions in underserved patients.
Nearly 3,500 patients were referred to the Roberts Individualized Medical Genetics Center for exome sequencing or other testing during the clinical program's first four years.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
Veterans Health Administration Precision Oncology Program Successfully Profiles Advanced Tumors
Premium
Since 2016, the VHA has routinely profiled molecular features in advanced cancers from vets in its care, even in rural locales, though challenges remain.
Expanded Germline Panel Testing in Cancer Patients Catches Risk Variants Missed by Focused Tests
Research presented at ACMG by Invitae suggests that clinically actionable variants in cancer patients are missed by germline testing that is not done with expanded panels.
Researcher Presents Promising Early Results on Color Cascade Testing Uptake at ACMG Meeting
A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.
While trials targeting actionable mutations are showing promise in some cancer cases, experts say such trials likely need to account for tumor heterogeneity.